Motesanib (AMG-706) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Allogeneic Stem Cell Transplantation [9.3]

Hormone Therapy [9.6] »

Motesanib (AMG-706)

May 15, 2015 by larryhbern

Angiogenesis related drug

Motesanib (AMG 706) is an experimental drug candidate originally developed by Amgen[1] but is now being investigated by theTakeda Pharmaceutical Company. It is an orally administered small molecule belonging to angiokinase inhibitor class which acts as an antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors.[2] It is used as thephosphatesalt motesanib diphosphate.

Posted in Uncategorized | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,656 other subscribers

Email Address
Recent Posts
- NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese September 14, 2021
- Standard Operating Procedures for Updating the Map of LPBI India August 24, 2021
- New avenues for research in membrane biology reveals the mobility of protein at work August 23, 2021
- Can the Public Benefit Company Structure Save US Healthcare? August 20, 2021
- Patients with type 2 diabetes may soon receive artificial pancreas and a smartphone app assistance August 13, 2021
- CNS immune interface August 9, 2021
- 3D printing: Improvising the Next-generation Batteries August 8, 2021
- Novartis uses a ‘dimmer switch’ medication to fine-tune gene therapy candidates August 7, 2021
- LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate in Financial Modeling & Econometrics as One Semester or as One Year Program open to Undergraduate and MBA students August 7, 2021
- Science Policy Forum: Should we trust healthcare explanations from AI predictive systems? July 31, 2021
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: